Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Metabolic dysregulation is regarded as an important driver in cancer development and progression. The impact of transcriptional changes on metabolism has been intensively studied in hormone-dependent cancers, and in particular, in prostate and breast cancer. These cancers have strong similarities in the function of important transcriptional drivers, such as the oestrogen and androgen receptors, at the level of dietary risk and epidemiology, genetics and therapeutically. In this review, we will focus on the function of these nuclear hormone receptors and their downstream impact on metabolism, with a particular focus on lipid metabolism. We go on to discuss how lipid metabolism remains dysregulated as the cancers progress. We conclude by discussing the opportunities that this presents for drug repurposing, imaging and the development and testing of new therapeutics and treatment combinations.

Original publication

DOI

10.1530/ERC-18-0048

Type

Journal article

Journal

Endocr Relat Cancer

Publication Date

09/2018

Volume

25

Pages

R435 - R452

Keywords

androgen, androgen receptor, breast, endocrine therapy resistance, oestrogen, Breast Neoplasms, Female, Humans, Lipid Metabolism, Male, Prostatic Neoplasms, Receptors, Cytoplasmic and Nuclear, Transcription, Genetic